Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: A post-hoc analysis of the Thai phase 3 efficacy trial RV 144

by Merlin L. Robb, Supachai Rerks-Ngarm, Sorachai Nitayaphan, Punnee Pitisuttithum, Jaranit Kaewkungwal, Prayura Kunasol, Chirasak Khamboonruang, Prasert Thongcharoen, Patricia Morgan, Michael Benenson, Robert M. Paris, Joseph Chiu, Elizabeth Adams, Donald Francis, Sanjay Gurunathan, Jim Tartaglia, Peter Gilbert, Don Stablein, Nelson L. Michael, Jerome H. Kim
Published 2018

Issues in women's participation in a phase III community HIV vaccine trial in Thailand

by Jaranit Kaewkungwal, Punnee Pitisuttithum, Supachai Rerks-Ngarm, Sorachai Nitayaphan, Chirasak Khamboonruang, Prayura Kunasol, Pravan Suntharasamai, Swangjai Pungpak, Sirivan Vanijanonta, Valai Bussaratid, Wirach Maek-A-Nantawat, Jittima Dhitavat, Prasert Thongcharoen, Rungrawee Pawarana, Yupa Sabmee, Mike W. Benenson, Patricia Morgan, Robert J. O'Connell, Jerome Kim
Published 2018

Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults

by Sorachai Nitayaphan, Punnee Pitisuttithum, Chitraporn Karnasuta, Chirapa Eamsila, Mark De Souza, Patricia Morgan, Victoria Polonis, Michael Benenson, Tom VanCott, Silvia Ratto-Kim, Jerome Kim, Darawan Thapinta, Robin Garner, Valai Bussaratid, Pricha Singharaj, Raphaelle El Habib, Sanjay Gurunathan, William Heyward, Deborah Birx, John McNeil, Arthur E. Brown
Published 2018

Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand

by Punnee Pitisuttithum, Supachai Rerks-Ngarm, Valai Bussaratid, Jittima Dhitavat, Wirach Maekanantawat, Swangjai Pungpak, Pravan Suntharasamai, Sirivan Vanijanonta, Sorachai Nitayapan, Jaranit Kaewkungwal, Michael Benenson, Patricia Morgan, Robert J. O'Connell, Jeffrey Berenberg, Sanjay Gurunathan, Donald P. Francis, Robert Paris, Joseph Chiu, Donald Stablein, Nelson L. Michael, Jean Louis Excler, Merlin L. Robb, Jerome H. Kim
Published 2018

The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope

by Mark S. De Souza, Silvia Ratto-Kim, Weerawan Chuenarom, Alexandra Schuetz, Somsak Chantakulkij, Bessara Nuntapinit, Anais Valencia-Micolta, Doris Thelian, Sorachai Nitayaphan, Punnee Pitisuttithum, Robert M. Paris, Jaranit Kaewkungwal, Nelson L. Michael, Supachai Rerks-Ngarm, Bonnie Mathieson, Mary Marovich, Jeffrey R. Currier, Jerome H. Kim, Supamit Chunsuttiwat, Nakorn Premsri, Chawetsan Namwat, Prayura Kunasol, Prasert Thongcharoen, Chirasak Khamboonruang, Valai Bussaratid, Wirach Maek-a-nantawat, Jittima Dhitavat, Pravan Suntharasamai, Swangjai Pungpak, Siriwan Vanijanonta, Jaranit Kaewkunwal, Amnat Khamsiriwatchara, Pawinee Jarujareet, Chirapa Easmila, Suchana Tabprasit, Viseth Ngauy, Robert Paris, Michael Benenson, Patricia Morgan, Arthur Brown, Mark De Souza, Rapee Trichavaroj, Nusara Thaitawat, Kanyasiri Kongnonkok, Boot Keawboon, Yuwadee Phuang-Ngern, Susan Mason, Sanjay Gurunathan, Jim Tartaglia, John G. McNeil, Robin Harkness, Claude Meric, Lynn Baglyos, Raphaelle El Habib, Don Francis, Carter Lee, Elizabeth Adams, Merlin L. Robb, Mark Milazzo, Amy Bolen, Beryl Wessner, Jeffrey Currier, Deborah L. Birx, Don Stablein, Terry Germanson, Len Dally, Jean Louis Excler, Jeffrey Berenberg
Published 2018